Business Wire

Yokogawa Releases SU10 Single Cellome Unit for Use in Biological Research

Share

Yokogawa Electric Corporation (TOKYO: 6841) announces that it has developed the SU10 Single CellomeTM Unit, a device that uses a nanopipette*1 to inject substances such as genes and drugs and aspirate intracellular materials at target locations in individual cells. Targeting the biological research market, the SU10 is being released on this date in Japan, with release in other markets such as the US to follow at a later date.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200317005039/en/

The SU10 Single Cellome Unit (Photo: Yokogawa Electric Corporation)

The SU10 Single Cellome Unit (Photo: Yokogawa Electric Corporation)

Through the development of such solutions, Yokogawa’s life innovation business is fostering the development of an industry centering on the use of smart cells, i.e. finely-designed, expression-controlled biological cells.

Development Background

Rapid advances in biotechnology are leading to the development of a bioeconomy that is expected to have a wide-ranging impact on fields ranging from agriculture to manufacturing and healthcare. One segment of this bioeconomy will be the smart cell industry, which will involve the manufacture of high-performance products such as biological medicines and replacements for petroleum-derived products using finely-designed, expression-controlled cellular organisms (smart cells). Smart cells are expected to bring about major changes in the energy and environmental industries as well as such fields as agriculture, manufacturing, and healthcare, and to solve a number of problems facing humanity.

In April 2018, Yokogawa established a Life Innovation Business Headquarters with the goal of promoting well-being for all. In addition to engaging in our existing life science and manufacturing solutions businesses targeting the pharmaceutical and food industries, the headquarters will work with our customers to develop new products and services that make use of Yokogawa’s core measurement, control, and information technologies, and provide one-stop solutions that revolutionize productivity throughout the pharmaceutical and food industry value chain, from basic research to manufacturing, logistics, and services.

There is keen interest within the cancer and immunology research fields in the use of single-cell analysis to clarify the causes of diseases and study pathological conditions, and this is expected to lead to advances in drug discovery research and the development of precision medicine and regenerative medicine. With the aim of fostering the development of a smart cell industry, Yokogawa has developed the SU10 for use by researchers in single-cell analysis.

Features

1. Minimally invasive*2 nanopipette
The SU10 enables the injection of substances such as genes and drugs and the aspiration of intracellular materials at targeted locations in individual cells. In contrast to the micrometer-sized pipettes that are used to perform such tasks, the tip of the nanopipette used in the SU10 has an outer diameter of approximately one hundred nanometers (nm), making it one of the smallest pipettes available for use in the biology research field*3. The tip of this nanopipette is much smaller than the cells that are analyzed with the SU10, making it minimally invasive and thereby allowing single-cell analyses of living cells.

2. Improved efficiency through the automation of analysis
An industry first*4, the SU10 automates a series of processes, starting with the detection of a cell surface and continuing with the penetration of the cell surface and the injection and aspiration of materials to and from the cell, all operations that up till now had to be performed manually by skilled researchers. With the SU10, injection and aspiration operations can be performed easily on living cells.

Hiroshi Nakao, a Yokogawa vice president and head of the Life Innovation Business Headquarters, commented on the release of the SU10 as follows: “Yokogawa is striving to achieve its Three Goals for sustainability by the year 2050. Our life innovation business is at the core of our efforts to promote well-being, which is one of the Three Goals. The SU10 offers new value to our customers who are conducting cutting-edge research and development work in biology and medicine. We will continue to grow our life innovation business by such means as expanding our product lineup with a micropipette-based single-cell analyzer that is under development, and are also considering the offering of such solutions on a subscription basis.”

Major Target Users

  • Universities, colleges, and research institutes that engage in life science research
  • Pharmaceutical and food companies

Main Applications

  • Cell analysis

*1 A pipette is a tube for injecting and aspirating a minute amount of material. A nanopipette is a tube with a tip diameter from 1 nanometer (nm) to less than 1,000 nm. One nm is equal to one-billionth of a meter. The term nanopipette also refers to a tube whose injection/aspiration volume is nanosized. Our nanopipette technology was developed by BioStinger, Inc., a US-based company that Yokogawa acquired in November 2019.
*2 Not causing much physical damage to a living organism. This term is used in the medical and biological fields.
*3 One micrometer (μm) is equal to one millionth of a meter, and one nanometer (nm) is equal to one billionth of a meter.
*4 Based on a March 2020 Yokogawa survey

For more information

https://www.yokogawa.com/solutions/products-platforms/life-science/single-cellome/su10

About Yokogawa

Founded in 1915, Yokogawa engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper. With the life innovation business, the company aims to radically improve productivity across the pharmaceutical and food industry value chains. The test & measurement, aviation, and other businesses continue to provide essential instruments and equipment with industry-leading precision and reliability. Yokogawa co-innovates with its customers through a global network of 113 companies spanning 60 countries, generating US$3.6 billion in sales in FY2018. For more information, please visit www.yokogawa.com.

The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.

Contact information

Yokogawa Electric Corporation
Public Relations, Integrated Communications Center
Yokogawa-pr@cs.jp.yokogawa.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

British Firm BitePRO Claim Mental Health Care Professionals Are At Risk Of Being Bitten26.2.2020 17:12:00 CETPress release

According to British firm BitePRO, mental health care and special educational needs professionals are at increased risk of being bitten by patients or pupils. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200226005697/en/ Healthcare nurse wearing BitePRO® Bite Resistant Clothing (Photo: Business Wire) Many nurses, care workers and teachers retire on medical grounds. They walk away from the profession they were once extremely passionate about, partly because medical experts have been able to identify that they suffer from real trauma and severe stress. Others, like Minnesota based Special Education Assistant Erin Gonzales are keen to continue and state: “I work at a school where human bites are a daily occurrence, but I work with kids with special needs. But honestly, I wouldn’t trade it for the world.” Oklahoma based Psychiatric Nurse Practitioner Miranda Hagan shares her desire and refuses to give up: “I have permanent sca

BIOCORP: Marketing Partnership on Mallya with iSage Rx in the Field of Digital Diabetes19.2.2020 17:00:00 CETPress release

Regulatory News: BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, today announced an alliance with US-based iSage Rx, LLC., a digital therapeutics company, focused on insulin dose optimization. In detail, the two companies are committed to integrating their respective technologies to simplify insulin dose capture and optimization. The integration of Mallya (a CE-marked connected device dedicated to insulin pens) into the iSage app (a clinically validated insulin titration platform cleared by the FDA) should enable patients with type 2 diabetes to simplify their insulin management. This will allow patients with diabetes to seamlessly capture, record, and store information about their insulin injections and while receiving automated guidance on how to adjust their insulin dose overtime ("titration"). Ryan Sysko, President and CEO of Amalgam Rx, Inc, said:

New Phase 3b Interim Data from STARDUST Study Show Two-Thirds of Patients with Moderately to Severely Active Crohn’s Disease Achieved Clinical Remission After Two Doses of STELARA® (ustekinumab)14.2.2020 07:00:00 CETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced interim data from the Phase 3b STARDUST study. At week 16, 79 percent of patients with moderately to severely active Crohn’s disease (CD) achieved clinical responsea and 67 percent were in clinical remissionb after receiving one ~6 mg/kg intravenous (IV) dose followed by one 90 mg subcutaneous (SC) dose of STELARA® (ustekinumab), open label.1 Intestinal ultrasound (IUS) responses were assessed and were detected as early as week 4.2 Week 16 data (digital oral presentation or DOP 13) and IUS response data (DOP 10) from STARDUST are being presented as part of a digital oral presentation at the 15th Congress of the European Crohn’s & Colitis Organisation (ECCO).1,2 The primary endpoint of the 48-week STARDUST study is comparative endoscopic responsec among adult patients with CD receiving ustekinumab maintenance therapy.3 At week 16, patients who achieved a ≥70 point decrease in Crohn’s Disease Activity Index scored

Edwards Launches New Compact Dry Vacuum Pump With the Highest Pumping Density on the Market13.2.2020 13:07:00 CETPress release

Edwards launch the new nXRi high performance compact dry pump, with lower input power and zero maintenance, bringing real performance improvements and cost benefits across a range of applications. Initial variants will provide pumping speeds of either 60 and 90 m3h-1 , four times more pumping speed than a similar sized dry pump. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200213005447/en/ Edward nXRi Compact Dry Vacuum Pump (Photo: Business Wire) Designed with size in mind, the compact footprint and height allow the Edwards nXRi dry pump to fit easily under a benchtop saving valuable space in the laboratory; and at under 30kg offers a highly mobile vacuum pump for changing work flows and environments. The pump is maintenance free for up to five years, with no tip-seal or oil change, for maximum uptime and reduced maintenance costs. The nXRi's 40% smaller footprint, compared to alternative dry pumps, assures seamless integ

Interactive Brokers Launches Bond Scanner to Help Investors Find the Best Pricing on Wide Range of Fixed Income Products12.2.2020 15:00:00 CETPress release

Interactive Brokers Group, Inc. (Nasdaq: IBKR) today announced it has created a Bond Scanner to help make finding the best prices on bonds easier and more transparent for clients and non-clients alike. “We believe we offer the lowest bond prices available. Investors should visit our Bond Scanner at ibkr.com/bonds, filter for bonds of interest, and then call their broker to compare,” said Steven Sanders, EVP of Marketing and Product Development at Interactive Brokers. “Clients benefit from our aggregation of price quotes from multiple electronic venues and institutional dealers,” he added. “We do not widen spreads nor are there hidden fees or markups. While some companies charge a large, hidden markup, we charge extremely low, transparent commissions. IBKR clients may provide liquidity to bond markets and improve pricing by entering their own pending orders into the book.” In addition to ultra-low, transparent pricing, the company offers a huge selection of fixed income products, includ

ADVA tackles GNSS jamming and spoofing with market’s first intelligent assurance solution11.2.2020 08:00:00 CETPress release

ADVA (FSE: ADV) today launched the industry’s first centralized GNSS monitoring and assurance tool. Using artificial intelligence (AI) and machine learning (ML) for comprehensive predictive maintenance, it addresses the key concerns of GNSS users around the globe. The new customer-owned tool enables users to collect and analyze huge amounts of information from across the network to remotely identify issues and protect networks from GNSS vulnerabilities, including jamming and spoofing attacks. It also helps to identify GNSS obstruction issues, detect blind/poor spots that appear over time and enable optimal antenna positioning. Built into ADVA’s Ensemble Controller network management suite with Sync Director, the solution enables customers to detect potential problems in advance, maintain the highest quality of network synchronization and significantly reduce opex. By complementing today’s limited distributed approach to GNSS assurance with a centralized-global system, it offers a major